Abstracts tagged "Immunotherapy"

Abstract Number: 850 • 2017 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System
Xerxes Pundole, Mohsin Shah, Noha Abdel-Wahab and Maria Suarez-Almazor, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Immune checkpoint inhibitors have become standard of care for many malignancies. Although these therapies are effective, they can activate the immune system resulting in…
Abstract Number: 1148 • 2017 ACR/ARHP Annual Meeting
Arthritis after Cancer Immunotherapy: Symptom Duration and Treatment Response
Melanie H. Smith¹ and Anne R. Bass^2,3, ¹Medicine, New York Presbyterian Hospital (Cornell), New York, NY, ²Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ³Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY
Background/Purpose: Checkpoint inhibitor immunotherapy has fundamentally changed the treatment for an actively expanding list of cancers, however its use is associated with immune related adverse…
Abstract Number: 1156 • 2017 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events from Checkpoint Inhibitor Therapy for Cancer: Long-Term Follow up Data
Cassandra Calabrese¹, Elizabeth Kirchner¹, Apostolos Kontzias¹, Laura Wood², Brian Rini², Vamsidhar Velcheti² and Leonard H. Calabrese¹, ¹Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, ²Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: The new and emerging field of immune related adverse events (irAEs) from cancer immunotherapies presents many unanswered questions. The spectrum of irAEs is broad…
Abstract Number: 1173 • 2017 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort
David Liew^1,2,3, Jessica Leung¹, Bonnia Liu¹, Jonathan Cebon^3,4, Albert Frauman^2,3 and Russell Buchanan¹, ¹Department of Rheumatology, Austin Health, Melbourne, Australia, ²Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, ³Department of Medicine, University of Melbourne, Melbourne, Australia, ⁴Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia
Background/Purpose: Immune checkpoint therapy with programmed cell death protein 1 (PD-1) inhibitors has led to significant survival benefits in the treatment of multiple cancers. This…
Abstract Number: 1462 • 2017 ACR/ARHP Annual Meeting
Induction of Immune Tolerance through an Epitope-Specific Vaccine Induces Clinical Amelioration in Patients with Rheumatoid Arthritis
Jin Hui Sherlynn Chan¹, Theodorus van den Broek², Jing Yao Leong¹, Maura Rossetti³, Roberto Spreafico⁴ and Salvatore Albani^1,5, ¹SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ²University Medical Center of Utrecht, Utrecht, Netherlands, ³University of California, Los Angeles, Los Angeles, CA, ⁴Synthetic Genomics, La Jolla, CA, ⁵KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: The manipulation of immune tolerance using immune checkpoints such as PD-1 is gaining progressive attraction in diseases such cancer where such manipulation would be…
Abstract Number: 1741 • 2017 ACR/ARHP Annual Meeting
Tolerance and Efficiency of Anti-Programmed Death 1 Antibodies in Patients with Cancer and Preexisting Autoimmune or Inflammatory Diseases
Francois-Xavier Danlos¹, Anne-Laure Voisin², Valérie Dyevre³, Jean-Marie Michot¹, Emilie Routier⁴, Laurent Taillade⁵, Stéphane Champiat¹, Sandrine Aspeslagh¹, Julien Haroche⁶, Laurence Albiges⁷, Christophe Massard¹, Nicolas Girard⁸, Stéphane Dalle⁹, Benjamin Besse⁷, Salim Laghouati², Jean-Charles Soria¹, Christine Mateus⁴, Caroline Robert⁴, Emilie Lanoy³, Aurélien Marabelle^1,10 and Olivier Lambotte¹¹, ¹Drug Development Department, Gustave Roussy Institut, Villejuif, France, ²Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy Institut, Villejuif, France, ³Service de biostatistique et d’épidémiologie, Gustave Roussy Institut, Villejuif, France, ⁴Department of dermatology, Gustave Roussy Institut, Villejuif, France, ⁵Department of medical oncology, Pitié Salpétrière Hospital, Paris, France, ⁶Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Department of medical oncology, Gustave Roussy Institut, Villejuif, France, ⁸8. Department of Respiratory Medicine, National Expert Centre for Thymic Malignancies, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France, ⁹Department of dermatology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France, ¹⁰Immunotherapy program, Gustave Roussy Institut, Villejuif, France, ¹¹Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France
Background/Purpose: Patients with auto-immune or inflammatory diseases (AID) treated by immune check-points inhibitors (ICI) are intrinsically susceptible to develop immune related adverse events (irAE). We…
Abstract Number: 1880 • 2017 ACR/ARHP Annual Meeting
Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience
Michael Richter¹, Olga Pinkston², Lisa Kottschade³, Heidi Finnes³, Svetomir N. Markovic⁴ and Uma Thanarajasingam⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ³Oncology, Mayo Clinic, Rochester, MN, ⁴Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and…
Abstract Number: 2119 • 2017 ACR/ARHP Annual Meeting
Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies
Emma Mitchell¹, Peter Lau², Chloe Khoo², Kortnye Smith², Benjamin Brady², Mark Shackleton², Grant McArthur², Ian Wicks^1,3,4 and Shahneen Sandhu², ¹Rheumatology, Royal Melbourne Hospital, Melbourne, Australia, ²Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, ³Medicine, University of Melbourne, Melbourne, Australia, ⁴Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia
Background/Purpose: Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (anti-PD 1) antibodies, are established therapies for advanced malignancies, including melanoma, and non-small cell lung…
Abstract Number: 2155 • 2017 ACR/ARHP Annual Meeting
Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center
Mohsin Shah¹, Jean Tayar¹, Noha Abdel-Wahab^1,2 and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: Immune checkpoint inhibitor therapy (ICI) has surfaced as a successful and robust treatment option in the fight to end cancer. As we gain more…
Abstract Number: 2702 • 2017 ACR/ARHP Annual Meeting
Tissue-Invasive T Cells in Rheumatoid Arthritis
Cornelia M. Weyand¹, Yi Shen², Yinyin Li¹, Eric L. Matteson³, Stuart Goodman⁴ and Jorg Goronzy⁵, ¹Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, ²Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Orthopaedic Surgery, Stanford Medical Center Outpatient Clinic, Redwood City, CA, ⁵Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: A key pathogenic event in rheumatoid arthritis (RA) is the formation of lasting lymphoid microstructures in the synovial tissue. It requires the transmigration of…
Abstract Number: 2902 • 2017 ACR/ARHP Annual Meeting
Inflammatory Arthritis Due to Immune Checkpoint Inhibitors: A Persistent Problem Requiring Immunosuppression
Laura Cappelli¹, Clifton O. Bingham III² and Ami A. Shah³, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as an important treatment for advanced malignancies. ICIs are a form of immunotherapy which block negative co-stimulation of…
Abstract Number: 13L • 2016 ACR/ARHP Annual Meeting
Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial
Jens Humrich¹, Caroline von Spee-Mayer², Elise Siegert³, Angelika Rose², Martina Bertolo⁴, Philipp Enghard⁵, Falk Hiepe⁶, Tobias Alexander⁷, Eugen Feist⁸, Andreas Radbruch⁹, Gerd R. Burmester¹⁰ and Gabriela Riemekasten¹¹, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁶Charité – Universitätsmedizin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁸Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁹Deutsches Rheumaforschungszentrum, Berlin, Germany, ¹⁰Charité – University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 1339 • 2016 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events of Checkpoint Therapy for Cancer: Case Series of a New Nosologic Entity
Cassandra Calabrese¹, Apostolos Kontzias¹, Vamsidhar Velcheti² and Leonard H. Calabrese¹, ¹Rheumatic & Immunologic Disease, Cleveland Clinic, Cleveland, OH, ²Hematology and Oncology, Cleveland Clinic, Cleveland, OH
Background/Purpose: The introduction of immunotherapy with biologic agents targeting immunologic checkpoints (i.e. CTLA4 and PD-1/PDL-1) have yielded impressive gains for cancer patients. These agents…
Abstract Number: 2934 • 2016 ACR/ARHP Annual Meeting
Clinical Assessment of the Monoclonal Anitbody, PRX003, a Potential Novel Treatment for Th17-Mediated Inflammatory Disease
Gene G. Kinney¹, Kenneth Flanagan¹, Michael Skov¹, Ronald Goldblum², Sue Griffith³, Robin M. Barbour¹, Wagner Zago¹, Ted Yednock¹, Martin Koller¹ and Dan Ness¹, ¹Prothena Biosciences Inc, South San Francisco, CA, ²Carlsbad Pharmaceutical Consulting, Inc., Carlsbad, CA, ³ClinPharma Services, Inc, San Diego, CA
Background/Purpose: Melanoma cell adhesion molecule (MCAM; CD146) is expressed on the surface of Th17 cells, which have the capacity to produce IL-17 and a multitude…
Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting
Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE
Jens Y. Humrich¹, Caroline von Spee-Mayer¹, Elise Siegert¹, Angelika Rose¹, Tobias Alexander², Falk Hiepe¹, Andreas Radbruch³, Gerd Burmester⁴ and Gabriela Riemekasten¹, ¹Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, ⁴Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].